ArticlePharmacoEconomics2010
The analysis of multinational cost-effectiveness data for reimbursement decisions: a critical appraisal of recent methodological developments.
Article in PharmacoEconomics, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic Evaluation alongside Multinational Studies: A Systematic Review of Empirical Studies.PloS one · 2015Pooled it
- The road not taken: transferability issues in multinational trials.PharmacoEconomics · 2013Pooled it
- Centre selection for clinical trials and the generalisability of results: a mixed methods study.PloS one · 2013Pooled it
- A cost-effectiveness analysis of early detection and bundled treatment of postpartum hemorrhage alongside the E-MOTIVE trial.Nature medicine · 2024Trial
- Hypothermia for perinatal asphyxia: trial-based resource use and costs at 6-7 years.Archives of disease in childhood. Fetal and neonatal edition · 2019Trial
- Trial
- Early Surgery versus Initial Conservative Treatment in Patients with Traumatic Intracerebral Hemorrhage (STITCH[Trauma]): The First Randomized Trial.Journal of neurotrauma · 2015Trial
- Design of an international multicentre RCT on group schema therapy for borderline personality disorder.BMC psychiatry · 2014Trial
- Article
- Article
- Cost-Effectiveness in Critical Care: A Systematic Review of Empirical Evaluations.Healthcare (Basel, Switzerland) · 2025Review
- A scoping review of statistical methods for trial-based economic evaluations: The current state of play.Health economics · 2022Article
- An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.PharmacoEconomics · 2019Review
- Article
- Conducting Economic Evaluations Alongside Randomised Trials: Current Methodological Issues and Novel Approaches.PharmacoEconomics · 2016Review
- Mind the Gap! A Multilevel Analysis of Factors Related to Variation in Published Cost-Effectiveness Estimates within and between Countries.Medical decision making : an international journal of the Society for Medical Decision Making · 2016Article
- Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool.BMC health services research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Evidence produced by multinational trial-based cost-effectiveness studies is often used to inform decisions concerning the adoption of new healthcare technologies. A key issue relating to the use of this type of evidence is the extent to which trial-wide economic results are applicable to every single country participating in the study. We consider what role cost-effectiveness analysis alongside multinational trials should have in assisting reimbursement decisions at jurisdiction and national levels. Using the proposed framework as a benchmark to evaluate their relative pros and cons, we then describe and review the statistical approaches used in the multinational trial-based cost-effectiveness literature. The results of the review are used to define the desirable characteristics a statistical method for the analysis of data collected from different jurisdictions should have in order to be consistent with the proposed framework. It is argued that Bayesian hierarchical models that use both patient- and country-level information are the most appropriate tool to analyse multinational trial-based cost-effectiveness data and facilitate the between-country generalizability assessment of the study findings. The merits of each approach are discussed, highlighting problems and limitations, in order to identify areas of future research.
Indexed as
Identifiers
21080734What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.